commiss decis octob relat proceed pursuant articl ec treati articl eea agreement iv pasteur mérieux merck english french text authent text eea relev ec commiss european commun regard treati establish european commun regard council regul februari regul implement articl treati amend act access spain portug articl thereof regard notif june merck amp pasteur mérieux sérum vaccin pursuant articl council regul eec regard commiss decis juli notifi oper fall scope regul eec constitut concentr mean articl regul regard parti request pursuant articl commiss regul eec amend regul ec treat notif pursuant regul eec applic mean articl notif mean articl regul regard agreement european econom area hereinaft refer eea agreement parti request januari pursuant articl protocol eea agreement notif extend articl eea agreement publish summari applic notif pursuant articl regul consult advisori committe restrict practic domin posit fact procedur notif concern oper pasteur mérieux sérum vaccin pmsv merck amp merck organ exist activ human vaccin relat busi territori defin ec efta jointli control compani pasteur mérieux msd snc jv oper organ set agreement parti date includ set call ancillari agreement overview agreement jv behringwerk ag behr juli oper examin pursuant articl ec treati month notabl august commiss inform parti doubt compat notifi oper commun competit rule invit submit satisfactori propos order prevent case close neg decis result parti gave viev obtain exempt articl undertak novemb amend substanti agreement behr grant specif right parti respect vaccin undertak result behr agreement conclus exclus manufactur licenc merck monoval haemophilu influenza hib vaccin prevent form mening germani recit conclus multival technolog transfer licenc agreement form recit amend agreement distribut vaccin germani recit undertak result conclus pierr fabr médicament sa pierr fabr exclus manufactur licenc merck monoval hib vaccin franc distribut right franc merck measl mump rubella mmr vaccin individu bival compon recit parti undertook jv provid commiss annual report volum price market share connect german french hib market french hepat measl mump rubella market entri forc eea agreement januari parti request januari extend notif articl eea agreement led undertak februari pursuant letter intent conclud finnish compani orion pharmaceut intern orion enter negoti grant orion exclus manufactur licenc merck monoval hib vaccin nordic efta countri june orion turn offer recit lederl praxi biolog lpb subsidiari pharmaceut compani american cyanamid compani activ vaccin market europ hib vaccin june compani lodg applic pursuant articl regul initi proceed articl ec treati institut mérieux parent compani pmsv merck smith kline beecham skb hereinaft refer complaint complaint consist part part relat lpb alleg firm abus domin posit member state suppli hepat vaccin lpb lpb request commiss adopt interim measur compel sell hepat vaccin lpb reason commerci term condit includ access registr document part relat format jv pmsv merck commiss letter februari pursuant articl commiss regul eec inform lpb consid suffici ground grant part applic part dealt context specif proceed notifi agreement pursuant regul lpb letter april inform commiss submit comment commiss letter intend respond public pursuant articl regul recit parti pmsv subsidiari institut mérieux subsidiari rhône poulenc privat french group chemic pharmaceut compani activ worldwid pmsv specialist manufactur human vaccin product blood protein relat biolog product turnov figur million ecu rhône poulenc pmsv rhône poulenc worldwid eea pmsv worldwid vaccin sale eea vaccin sale pmsv eea turnov immunoglobulin vivo diagnost sera ecu million merck major compani activ worldwid pharmaceut total turnov million ecu worldwid vaccin sale eea vaccin sale merck form separ divis vaccin busi merck activ field immunoglobulin vivo diagnost sera april feder trade commiss approv joint ventur pmsv indirect subsidiari connaught laboratori merck research develop market multival combin antigen vaccin paediatr vaccin unit state america parent compani distribut vaccin jv promot merck distribut vaccin manag health care organ connaught laboratori privat paediatrician parti enter similar promot agreement exist paediatr vaccin product busi jv relat human vaccin specif immunoglobulin vivo diagnost sera addit product partner time time determin decis cover addit product vaccin product specif immunoglobulin transfer pmsv jv rabi tetanu immunoglobulin life save product product routin administ vaccin anim bite wound diagnost refer strictli tuberculin test connect pmsv tuberculosi bcg vaccin sera minor product ecu turnov eea sera pmsv continu provid public health reason import product group oper pmsv merck activ relat human vaccin characterist vaccin sector vaccin amp import vaccin public health gener recogn vaccin minor diseas requir amp effort develop vaccin vaccin technolog continu guid refer epidemiolog studi pharmaceut amp remain complex costli long term enterpris requir larg team multi disciplinari approach cost develop product high ow enforc safeti regul control risk claim damag expens clinic trial fundament research increasingli base biotechnolog recombin dna technolog conduct special compani scientif institut univers protect research result patent right licens vaccin manufactur return royalti payment object combin exist vaccin multival vaccin amp effort involv relat reformul antigen effect combin antigen except combin inactiv vaccin live vaccin sort combin theori area paediatr obligatori recommend vaccin develop seri vaccin combin includ dtp diphtheria tetanu pertussi hib polio hepat call ideal children vaccin gener recogn prioriti benefit ideal heat stabl vaccin includ fewer inject fewer clinic visit increas famili accept result coverag cost save regard suppli needl syring vial cold chain storag space administr medic personnel greater eas deliveri simplifi record keep effici post administr monitor servic vaccin manufactur ideal antigen combin base improv call acellular pertussi antigen inject polio antigen recombin hepat antigen pertussi result perceiv side effect cell pertussi perceiv effect reason immun pertussi form dtp decad experi back gener paediatr itali denmark polio vaccin gener immun countri oral form base attenu viru multival inject polio vaccin requir pmsv rivm dutch public health institut produc base proprietari inject polio vaccin base kill viru vaccin kill viru possibl healthi child develop diseas vaccin total exclud hepat plasma base vaccin previous produc pmsv longer approv health author view blood relat risk vaccin product product vaccin complex process involv growth cell cultur purif bulk vaccin formul fill packag product process subject proprietari case hepat product patent protect manufactur facil control qualifi nation regulatori author legal standard provis countri product locat includ good manufactur practic regulatori qualif manufactur facil part author vaccin product chang product facil chang product process requir undergo qualif licens procedur vaccin vaccin compani worldwid activ manufactur product place nation product qualif recogn relev author countri vaccin distribut contrast pharmaceut product countri vaccin view biolog natur inher risk product batch failur batch releas relev nation control laboratori batch vaccin distribut vaccin compani distribut product eea countri countri basi nation differ spite technic harmon achiev relat epidemiolog hib vaccin paediatr northern europ hepat paediatr southern europ immun scheme vaccin vaccin compulsori countri recommend eea countri time schedul ident vaccin vari countri countri paediatr vaccin tuberculosi vaccin bcg dtp polio vaccin pharmacovigil observ unexpect effect vaccin countri batch releas requir fulfil nation level wide vari price reimburs mechan eea countri vaccin free charg vaccin countri patient receiv partial complet reimburs differ demand structur nordic countri netherland greec suppli vaccin virtual exclus gener public health institut produc vaccin purchas product bulk finish form public tender iceland norwai finland institut import monopoli ireland itali spain unit kingdom vaccin purchas public tender doctor choos vaccin prescrib rang recommend vaccin eea countri chiefli franc germani vaccin larg extent suppli privat market distribut wholesal pharmaci directli hospit case germani doctor vaccin manufactur requir sale forc market successfulli product countri differ nation prefer present form vaccin vial singl dose multi dose multi chamber syring vari characterist result signific differ vaccin vaccin countri countri illustr refer largest nation market eea franc germani itali account sale ecu million itali countri recommend gener paediatr vaccin hepat sale vaccin total total sale virtual sale hib vaccin vaccin turn import vaccin germani sale amount total vaccin sale sale flu vaccin germani worth ecu million total sale franc hepat flu vaccin repres sale ecu million give total sale posit parti vaccin market gener overview merck european vaccin portfolio consist mmr individu bival compon hib hepat pneumococcu enter european vaccin market earli begin merck staff dedic vaccin netherland spain case small group germani hepat vaccin promot itali gener hospit sale forc merck work exclus independ distributor public health institut distribut vaccin portfolio europ distribut complet portfolio occur eea countri germani vaccin distribut behr sale germani repres merck vaccin sale eea total ecu million merck total combin turnov product eea total sale account hepat vaccin sale itali vaccin distribut franc pmsv larger vaccin oper eea offer vaccin combin diseas distribut vaccin occur predominantli subsidiari nordic dutch greek public health institut recit independ distributor plai role germani roehm connaught vaccin portug greec ireland flu vaccin eea pmsv present eea countri pmsv vaccin sale concentr countri franc account pmsv total vaccin sale eea pmsv produc vaccin offer franc except flu product distribut pmsv independ distributor command market hepat account market skb account remain part paediatr vaccin dtp polio bcg hib mmr french paediatrician french doctor prescrib half vaccin pmsv strong posit partial ow abil offer complet paediatr rang reliev prescrib doctor maintain distribut relationship inform exchang includ medic represent visit refriger discount produc unit kingdom sale account german sale pmsv total turnov pmsv explain hepat vaccin offer franc wide accept mmr vaccin rental product portfolio overlap exist product parti exist product portfolio show overlap hib mmr monoval compon hepat pneumococc vaccin pmsv suppli hib vaccin product product origin canadian subsidiari connaught laboratori vaccin launch eea market market brand merck hib vaccin enter eea market hib vaccin paediatr vaccin prevent form mening mmr clinic studi show increas side effect mump strain skb pmsv led skb withdraw mump mmr product eea market whilst pmsv offer franc itali greec leav merck produc wide accept mump mmr vaccin berna swiss base competitor regist mmr greec austria mmr market import sale total ecu million commun countri germani itali franc unit kingdom spain belgium total ecu million complet mmr famili countri estim improv mump strain year hepat vaccin longer produc plasma basi view blood relat risk current formul produc genet engin subject patent claim consider uncertainti legal valid precis scope patent claim hepat vaccin technolog patent applic grant oppos partli revok appeal reason merck skb decid enter cross licens arrang relat right licens research institut cross licenc parti licens acquir right compani licenc affili jv allow produc access patent right involv order avoid uncertainti cost litig licenc merck skb respect right merck skb hepat vaccin offer berna unit kingdom compani medeva berna receiv teijin japanes produc distribut right hepat vaccin switzerland sale portug spain itali greec medeva present appeal judgment unit kingdom high court found product infring biogen patent licens skb pmsv licens sell recombin hepat vaccin monoval franc franc licenc includ hepat multival franc pmsv believ obtain registr recombin monoval hepat vaccin franc pneumococc vaccin prescrib order prevent pneumococc pneumonia patient immunocompromis notabl patient spleen remov chronic condit make risk pneumococc pneumonia chronic obstruct pulmonari diseas heart diseas liver diseas group gener older adult size target group potenti larg vaccin remain controversi illustr fact vaccin commerci mid europ north america combin turnov eea countri estim total ecu million franc largest singl market estim turnov ecu countri vaccin sold regist provid name patient basi note pneumococc vaccin pneumococc conjug vaccin develop vaccin expect infant children prevent type mening ear infect virtual overlap target group technolog futur vaccin parti activ amp work seri vaccin amp pipelin vaccin stage develop overlap hepat varicella vaccin normal children pre clinic trial research overlap pneumococc conjug vaccin merck acellular pertussi inject polio vaccin research programm geograph specif germani present pmsv merck monoval hib measl rubella vaccin sale germani import term turnov market monoval hib market total sale ecu million vaccin belong pmsv canadian subsidiari connaught laboratori realiz merck vaccin introduc distribut behr competitor lpb introduc vaccin achiev market share parti agreement grant behr exclus licenc hib patent manufactur distribut merck monoval hib vaccin sale germani licenc enabl behr establish manufactur facil arrang manufactur subcontract merck license commun merck jv monoval rubella market estim turnov ecu million total dose bulk rubella vaccin sold part mmr market realiz turnov ecu million parti monoval rubella vaccin account number dose sold remain vaccin sold skb wellcom internation oper vaccin produc parti combin share german monoval measl market turnov ecu remain market share realiz skb vaccin bulk measl vaccin equal sold part mmr vaccin greec present parti sell mmr vaccin independ distributor greek market vaccin sold greec total turnov ecu berna swiss base vaccin produc regist mmr vaccin greec portug portugues pneumococc vaccin market total turnov factori price ecu parti offer vaccin vaccin regist portug sale made name patient basi servic franc parti grant pierr fabr agreement june distribut right franc merck mmr individu bival compon right exclus jv french affili regard mmr monoval mump bival measl mump pierr fabr option merck trademark franc mmr monoval mump bival measl mump trademark pierr fabr agre durat agreement year option sole discret pierr fabr year prolong engag activ regard compet product agreement june pierr fabr receiv exclus licenc hib patent manufactur merck monoval hib vaccin sale franc licenc enabl pierr fabr establish manufactur facil arrang manufactur subcontract merck license commun merck jv right grant pierr fabr affect jv french affili sell merck monoval hib vaccin franc regulatori medic problem aris connect monoval hib prp vaccin present market pmsv franc durat licenc year year prolong sole discret pierr fabr nordic efta countri iceland norwai sweden finland pmsv merck hib vaccin activ compet nordic efta countri monoval hib market sweden norwai vaccin hib vaccin sold sale total ecu million sweden ecu million norwai pmsv hib vaccin account sale swedish associ paediatrician recommend pmsv prp hib vaccin gener vaccin infant sweden recommend clinic trial last june swedish born children involv pmsv hib vaccin led merck vaccin disappear market staten bakteriologiska laboratorium june holder import monopoli vaccin distributor merck vaccin sweden offer norwegian state institut enter june suppli agreement pmsv parti sign letter intent orion agre enter negoti grant orion exclus licenc manufactur merck monoval hib vaccin sale nordic efta countri licenc line enter pierr fabr franc orion inform parti june investig possibl introduc vaccin nordic countri decid turn offer parti offer remain valid interest parti notifi oper object busi scope jv primari purpos object jv creation develop multival vaccin result signific public health benefit recit distribut exist product countri market creation jv futur research vaccin concentr specif european requir respect epidemiolog biolog characterist vaccin adapt dosag combin tradition prefer deliveri system post clinic phase ii onward ii relat technolog improv elimin preserv improv vector deliveri system oral deliveri dna rna base research busi scope jv facilit research overse develop regist arrang manufactur principl pmsv merck distribut market sell ec efta vaccin immunoglobulin vivo diagnost sera addit product partner time time requir transfer exist busi jv jv set form société en nom collectif snc french law capit ff million merck french subsidiari merck close merck pmsv hold ownership snc assembl partner compos vote member repres parent compani dai dai activ manag gérant form french société anonym directoir conseil de surveil parent equal sharehold equal represent parti transfer jv exist product registr right exclus licens jv exist patent own licens right retain permit continu manufactur product sole sale jv territori ii sale territori right parti exist prior jv exist product right copyright trade dress tradenam licens transfer jv addit pmsv transfer licens tangibl asset fond de commerc capit stock subsidiari parent transfer jv respect right oblig distribut agreement parti agreement merck behr german distributor jv conclud behr agreement vaccin parent agre subject parti right transfer licens jv product right registr market pipelin product vaccin late develop stage countri territori aris option jv render reason assist enabl jv obtain right jv elect commerci product origin parti permit jv obtain product registr product territori subject retent registr origin parti requir continu manufactur product sole sale territori ii sale jv territori jv elect bring product market transfer licens product right product merck hepat parti jv pursu develop fund direct post phase ii test post launch develop studi support registr market product territori patent result develop work fund jv belong jv territori parti engag relev develop work territori patent product earli develop stage futur pipelin product origin parti commenc post phase ii test offer product jv jv accept product jv receiv exclus licenc subject parti right territori product right mechan product registr share develop cost intellectu ownership ident pipelin product jv bring product market origin parti transfer licens right parti territori term favour offer jv develop committe assembl order formul implement direct amp strategi jv parent benefit jv territori develop committe overse commun amp activ parent undertaken jv includ commun discoveri overse develop jv multival product identifi effici util resourc parent develop activ identifi multival product develop advis manag bodi jv patent result develop work fund jv respect multival product belong jv provid parent grant exclus worldwid royalti bear licenc arrang administr support servic includ account treasuri manag inform currenc hedg financi servic legal medic regulatori servic provid parent cost basi merck pmsv suppli cost basi jv requir exist product right parent transfer licens jv futur product respect parent origin jv sell monoval includ multival product pmsv long capac competit cost complet finish jv multival compon merck jv audit cost year event jv determin cost reason procur relev servic permiss term patent licenc relat product parti provid substanti advantag term exist parti offer connaught laboratori grant jv exclus subject parti right licenc territori product right futur product term year agreement termin event connaught ceas pmsv affili jv manag exist distribut arrang connaught territori option jv serv connaught distributor exist product subject parti right durat agreement termin automat end year extend mutual consent write merck sell interest time pmsv option purchas competit parent agre sell suppli licens parti prior termin jv product compet product territori merck period year sale interest sell suppli licens parti jv product sold jv prior sale merck interest compet product parent solicit employe jv leav jv year termin jv sale interest behr agreement behr behr subsidiari german chemic concern hoechst ag produc distributor pharmaceut product therapeut diagnost behr realiz worldwid turnov ecu million account vaccin sale vaccin sale concentr germani substanti part german sale product produc merck distributor pneumococc mmr hib agent hepat make behr import vaccin manufactur distributor germani account half turnov realiz german vaccin market germani behr activ eea except flu vaccin distribut franc cassenn subsidiari hoechst ag continu distribut merck exist vaccin hib recit promot futur jv vaccin behr germani subject right parti exclus jv sole distributor merck exist mmr compon pneumococc vaccin vaccin account german market sole agent distribut merck exist hepat vaccin behr sell account jv vaccin command half german hepat market exclus promot jv futur varicella mmr varicella hepat vaccin promot agreement agreement parti promot lend market forc promot medic profess product origin parti parti retain final respons price qualiti standard qualiti quantiti promot effort dedic product behr make sale germani respons unsolicit request behr distribut product parti compet vaccin behr appoint exclus vaccin develop behr multival parti enter set agreement behr behr option procur jv requir hib acellular pertussi hepat antigen inclus multival develop behr sale germani make sale germani respons unsolicit request last behr develop multival time date procur jv antigen multival minimum year market event develop work basi multival technolog transfer licenc agreement enabl behr sell make made behr multival licens technolog jv oblig licens undertak exploit licens technolog defin multival germani view hepat patent situat recit behr right respect multival develop merck hepat antigen limit sale product trademark product registr vaccin own jv behr produc vaccin subcontractor jv agreement behr opportun develop distinct set multival sale germani base antigen jv antigen parti antigen behr free exploit germani sever intellectu properti right creat develop multival antigen jv parti observ commiss receiv comment notifi oper essenti content publish pursuant articl regul lpb skb compani competit market involv notifi parti lpb object commiss intent exempt jv view oligopolist natur european vaccin market lpb compani account close sale paediatr vaccin jv immedi market share paediatr human vaccin close commun lpb believ jv detriment effect futur structur competit combin resourc parti sever hinder abil compani enter market paediatr multival product lpb consid develop paediatr hexaval dtp hib hepat polio vaccin dramat effect sale monoval includ compani includ lpb access hepat due lpb exception broad patent face sever threat abil remain vaccin market lpb consid access hepat antigen crucial view current paediatr vaccin hepat itali spain portug acknowledg public health administr northern europ spread hepat viru effect control vaccin call adult high risk group administr intend recommend paediatr vaccin increment cost relat benefit launch hexaval vaccin lpb spur univers immun hepat preced mmr show lpb believ reason current schedul applic hepat alter hexaval product lpb argu commiss oblig measur ensur likelihood effect competit parti multival vaccin maintain argu agreement behr provid adequ remedi neg effect jv competit futur market multival vaccin contrari agreement remov behr import partner manufactur forc seek allianc surviv confront market power jv lpb conclud commiss exempt jv requir jv suppli hepat lpb global vaccin manufactur addit jv commiss obtain notifi parti reaction lpb comment factual clarif parti confirm itali countri gener paediatr recommend hepat vaccin spain vaccin recommend infant seventeen region health author put recommend practic region author purchas vaccin offici recommend portug vaccin made free year adolesc infant commiss receiv observ skb parti jv global vaccin produc skb summar observ competit commun vaccin produc depend innov access technolog vaccin compon activ jv limit market distribut ancillari administr function basi skb jv competit innov forc vaccin market wide scope extend merck pmsv current futur vaccin technolog jv normal competit process vaccin market europ ensur access technolog restrict durat arrang consider longer usual distribut jv skb believ commiss retain abil review effect jv competit vaccin market date improv technolog product result format jv improv distribut undertak parti relat germani franc substanti cooper arrang enabl merck pmsv collabor product limit period time bring need combin product paediatr vaccin market skb believ term jv respect prevent competitor bring innov product market place detriment public view skb observ access vaccin technolog parti amend exclus patent licenc eea jv explicitli allow jv cross licens intellectu properti right develop manufactur eea exist futur vaccin manufactur ii legal assess articl ec treati articl eea agreement agreement undertak pmsv merck undertak mean articl ec treati eea agreement set agreement date parti organ exist activ human vaccin busi territori defin ec efta jointli control compani ancillari agreement notifi agreement mean articl ec treati eea agreement relev market relev product market vaccin ensur immun specif diseas form product market viewpoint consum substitut exist vaccin protect diseas vaccin present specif characterist respect develop product technolog develop produc vaccin product subject specif regulatori requir reason multival vaccin consid belong product market equival monoval vaccin launch multival accept health author medic commun effect replac part equival monoval suffici product belong product market consum prescrib adopt quickli distinct usag multival prefer gener immun monoval brush immun booster protect person retain produc order cope advers reaction antigen includ multival exampl process found past experi dtp mmr multival relev geograph market present condit competit prevail eea countri respect distribut vaccin reason laid recit factor tradit prefer nation produc close relat state reason expect condit competit relat epidemiolog nation legal framework medic tradit chang futur geograph market nation past experi dtp mmr shown case multival restrict competit parti parti transfer mechanismu section notifi oper jv european distribut network exist european vaccin portfolio european orient amp activ post clinic phase ii onward result vaccin vaccin technolog transfer strengthen competit oblig summar recit parent elimin competit european vaccin market parti consid actual potenti competitor actual competit parti competit vaccin market recit creation jv lead appreci restrict competit german monoval rubella measl market recit regard greek mmr market recit note parti sell vaccin greec side effect note mump strain pmsv recit lead pmsv possibl insist nation health author withdraw mmr vaccin elimin weaken actual competit creation jv consid appreci restrict competit reason potenti competit nation mmr market restrict state recit regard german monoval hib market licenc recit result competit situat relev market merck distributor behr replac behr act independ competitor market market parti vaccin portugues pneumococc market recit market character extrem limit total turnov ecu consequ absenc econom viabl market potenti vaccin lack registr product sale occur absenc distribut effort manufactur specif request doctor call name patient sale view possibl doctor bui vaccin competitor offer eea margin import market creation jv appreci effect potenti competit exist product view patent situat hepat recombin vaccin recit pmsv posit market risk litig vaccin franc pmsv consid potenti competitor eea market conclus strengthen pmsv belief view characterist product obtain registr franc merck possess patent licenc product regist eea countri view hepat market potenti franc sale total ecu million merck total turnov eea merck consid potenti market entrant french market take account french prefer pre fill syring footnot page creation jv lead appreci restrict competit french hepat market regard mmr market consid absenc jv pmsv engag amp amelior mump strain enter mmr market year exist substanti demand multival vaccin merck mump strain recit wide accept merck view limit distribut effort need consid realist market entrant eea mmr market establish creation jv lead appreci restrict competit mmr market eea countri pmsv develop improv mmr vaccin compet merck vaccin monoval hib vaccin view epidemiolog recit limit market potenti itali spain portug greec sale occur merck vaccin sold germani sweden norwai sale made independ distributor spain jv grant manufactur licenc merck monoval hib vaccin independ parti franc recit parti pierr fabr decid appoint merck license subcontractor product vaccin basic commerci term quantiti price promot eea countri merck vaccin sale forc recit product regist denmark ireland austria view presenc vaccin notabl pmsv lpb market current level demand vaccin absenc circumst lead specif request merck product expect merck enter market monoval hib market eea countri itali spain portug greec germani franc conclus corrobor imposs find independ parti introduc manufactur licenc vaccin nordic efta countri recit creation jv result restrict competit monoval hib market creation jv consid lead appreci elimin competit pneumococc market parti sell eea countri potenti entri countri realist view limit turnov market potenti vaccin market recit ii futur monoval futur product advanc stage clinic trial pipelin product realist assum parti view past perform financi strength exist vaccin knowledg consid potenti competitor monoval actual amp portfolio show overlap hepat varicella creation jv result appreci restrict competit european vaccin market jv post phase ii clinic trial distribut final product assess restrict competit parti monoval vaccin earlier stage amp futur pipelin product difficult view extrem broad rang futur research lack precis indic chanc bring success product market parti remain autonom basic amp decis alloc respect budget respect earli phase clinic work fundament basic research bui basic research undertaken special institut market orient develop committe jv recit amp activ parent includ commun discoveri discuss exclud discuss lead coordin basic amp trigger regard paediatr multival jv parti unit state america recit view parti import posit vaccin market worldwid presenc amp budget coordin appreci effect amp futur pipelin product eea iii multival multival develop recit parti product portfolio exist vaccin antigen antigen advanc stage develop develop mmr varicella multival merck dispos mmr vaccin pmsv improv vaccin recit varicella vaccin normal children late stage develop recit product portfolio overlap combin parti formul multival regard paediatr combin includ dtp acellular inject polio hib hepat recit antigen access hib accept absenc jv merck theoret obtain bulk suppli vaccin consid commod product dtpwholecel current success pmsv dtpwholecel hib combin germani appear merck start develop programm basi bulk suppli result vaccin market time competitor possess perform multival base acellular pertussi antigen conclud econom viabl action accept parti consid potenti competitor develop multival simpli abil obtain access miss antigen licenc proprietari patent possibl bulk suppli manufactur potenti antigen develop hepat mening antigen remain antigen dtpa hib hepat viabl action obviou licenc grant view inher complex safeti stabil problem antigen includ multival give rise liabil risk contractu relat manufactur requir addit formal licenc possibl bulk suppli ongo cooper specialist origin parti antigen blend multival involv continu wide rang exchang inform basi trust relationship amp team action constitut workabl flexibl altern develop wide rang multival adapt european countri view epidemiolog health polici approach tradit prefer jv intend launch eea market conclud creation jv result appreci restrict mmrvaricella multival market effect creation jv parti exist immin vaccin vaccin technolog notifi agreement parent compani suppli licens vaccin vaccin technolog parti eea jv jv combin individu parent portfolio primari effect jv relat produc result jv increas sourc autarki relat exist immin antigen pipelin product vaccin technolog produc view arrang limit possibl collabor parent compani jv sourc access miss antigen vaccin technolog deliveri system vaccin combin technolog sourc import develop multival paediatr combin posit parti relev market result exist immin vaccin technolog appreci restrict competit parti futur vaccin vaccin technolog assess effect creation jv produc relat futur antigen vaccin technolog refer made wide rang diseas vaccin develop success lead consider sale opportun hepat herp aid singl firm consid view relat cost estim cost million bring vaccin market capabl cover field limit number vaccin produc european presenc present spend worldwid basi ecu million year vaccin relat amp pmsv skb merck lpb engag research produc public privat nation compani concentr bulk paediatr market dtpwholecel oral polio recogn import costlier recent dna relat research develop vaccin presenc numer special compani scientif institut univers engag basic biotechnolog research consid potenti competitor futur vaccin market view number potenti competitor wide rang futur vaccin vaccin technolog indic creation jv lead appreci restrict competit reduc sourc possibl produc futur vaccin vaccin technolog restrict competit result behr agreement continu sole distribut agreement merck mmr compon vaccin recit restrict intra brand competit product germani jv prevent appoint distributor consid appreci restrict competit view import market posit exist merck origin vaccin market share behr lead vaccin produc distributor germani agreement appreci effect inter brand competit market behr distribut compet brand whilst lose exclus pneumococc vaccin view limit market potenti merck transfer price revenu ecu year continu sole agenc agreement merck hepat vaccin recit restrict intra brand competit product jv prevent appoint agent equal restrict effect inter brand competit mmr agreement consid constitut appreci restrict competit appoint behr exclus promot prior exist parti right jv germani jv futur hepat varicella mmr varicella vaccin recit consid constitut appreci restrict competit limit jv abil appoint independ distributor product prevent behr distribut compet product behr establish loyalti medic commun futur product possibl unrealist exclus jv licenc jv behr multival technolog transfer licenc agreement relat multival respect jv monoval hib antigen merck origin acellular pertussi hepat antigen allow behr make multival hepat rectit sell behr multival germani constitut view market potenti multival appreci restrict competit germani vaccin produc receiv jv licenc make sell multival base jv kei antigen germani grant exclus patent trademark licenc jv behr manufactur distribut merck monoval hib vaccin germani constitut view market share vaccin germani appreci restrict competit merck jv grant licenc vaccin produc manufactur distribut product activ sale germani restrict competit result agreement pierr fabr grant exclus patent licenc jv pierr fabr manufactur distribut merck monoval hib vaccin franc constitut view market potenti vaccin franc appreci restrict competit merck jv grant licenc vaccin produc manufactur distribut regulatori medic problem aris connect monoval hib vaccin present market pmsv franc product activ sale franc exclus jv french affili regard mmr monoval mump bival measl mump distribut right merck mmr monoval bival compon grant pierr fabr franc constitut view market potenti merck mmr monoval mump vaccin franc appreci restrict competit vaccin distributor distribut product franc appreci effect trade member state contract parti creation jv lead worldwid vaccin produc bring total european vaccin busi post phase ii amp distribut view parti actual potenti strength vaccin amp product distribut appreci direct influenc pattern trade member state contract parti actual futur market creation jv result appreci restrict competit behr agreement agreement pierr fabr appreci effect trade member state contract parti limit scope right activ market product germani franc agreement render difficult unrestrict flow trade treati eea agreement intend creat conclus creation jv pmsv merck fall foul articl ec treati articl eea agreement respect effect german monoval measl rubella market french hepat market mmr mmr varicella varicella hepat market futur pipelin product concern field amp view effect parti jv relat agreement restrict competit limit appreci extent access competitor exist immin vaccin vaccin technolog paediatr combin distribut agreement mmr compon vaccin germani franc german hepat agenc agreement multival technolog transfer licenc agreement hib manufactur licenc behr pierr fabr fall foul articl ec treati eea agreement articl treati articl eea agreement jv improv product distribut promot technic econom progress promot technic progress jv parti discuss experi amp activ cooper regard develop activ post phase ii clinic trial european orient vaccin put exist antigen vaccin technolog portfolio dispos jv develop perform vaccin view inform inflow distribut network cover eea countri adapt specif individu countri avoid amp overlap benefit parti respect strength lead qualit promot technic progress indic improv refer expampl develop multival vaccin recit gener recogn prioriti view numer advantag immun fewer inject clinic visit medic administr cost increas famili accept lead coverag rate lead medic author repeatedli argu develop paediatr multival combin dtp polio hib hepat jv start develop programm combin vaccin produc possess antigen abil adapt combin specif nation vaccin import view epidemiolog differ eea countri tradit prefer antigen made specif combin jv posit bring market sooner realiz import technic progress field monoval vaccin jv pool experi stimul technic progress bring perform vaccin market illustr refer varicella vaccin pmsv possess exist vaccin immunocompromis children vaccin normal children clinic phase ii iii registr expect merck unit state america varicella vaccin normal children final stage registr merck vaccin storag freezer facil common european vaccin distribut chain estim due combin merck vaccin pmsv stabil factor allow storag refriger vaccin normal children sooner eea case absenc jv varicella vaccin develop uniqu european mmr varicella vaccin involv pmsv measl merck mump joint rubella strain similar relat futur pneumococc conjug vaccin parti estim vaccin serotyp parent order optim protect major strain pneumococcu mening pneumonia otiti media ear infect protein carrier medium parti conjug jv vaccin potenti fewer advers effect protein carrier technolog direct european epidemiolog serotyp choic develop made sooner jv advantag technic progress expect develop technolog vaccin product improv elimin preserv improv vector deliveri system oral deliveri dna rna base research improv distribut recit merck enter eea market year ago limit presenc notabl except germani jv base pmsv exist comprehens distribut network assur coverag merck exist futur vaccin eea specif french market concern manufactur licenc merck monoval hib vaccin distribut right mmr mono bival grant pierr fabr establish vaccin distributor franc pierr fabr begin paediatr vaccin product rang possibl take distribut vaccin vaccin produc franc market pauciti independ distributor recit barrier entri paediatr vaccin distribut franc remov agreement jv pierr fabr lead improv distribut vaccin paediatr vaccin benefit consum achiev technic progress improv distribut respond genuin public health concern numer organ includ world health organ european parliament underlin benefit accur stabl easi administ vaccin public health consum jv state stimul speed develop vaccin mono multival adapt eea countri exist futur vaccin eea provid sooner case increas rang exist futur mono multival eea consum allow fair share result benefit indispens order develop paediatr multival vaccin produc access requir antigen pmsv merck mmr varicella develop synergi produc produc paediatr hexaval partnership requir pmsv merck conclud agreement produc view lack similar synergi possibl pediatr hexaval cooper network limit exchang licenc bulk suppli multipl partner consid rigid achiev ambit jv develop wide rang multival adapt european countri requir open end reach cooper adapt unforeseen circumst result continu exchang inform parti believ jv mechan flexibl achiev addit jv legal altern recit share total hepat patent right pmsv fact parti share intellectu properti right facilit realiz paediatr multival basi hepat antigen ambit parti develop wide rang multival adapt eea countri develop paediatr multival hepat view epidemiolog hepat southern europ crucial indispens scope jv extend develop paediatr multival vaccin jv structur flexibl enabl futur opportun account promot develop monoval vaccin technolog addit fear develop multival hamper view imposs separ multival develop work vaccin research need support kei programm involv preserv plan research antigen includ combin collabor research deliveri system vector ii inher reluct partner point proprietari import mulival rang indispens proper function jv achiev advantag scope jv extend joint distribut exist futur vaccin jv conclus base consider restrict competit result joint distribut extrem limit consequ weak presenc merck europ realist assum merck develop europ wide distribut network merck unlik newcom european vaccin market lpb paediatr pharmaceut sale forc build ii merck subsidiari vaccin busi minor import total sale consequ group intern invest prioriti iii physic distribut vaccin requir consider invest cold chain extend distribut relationship multipl independ parti view limit result achiev past year notabl except germani limit number vaccin distributor european wide presenc merck conclud distribut agreement notabl pmsv skb altern distribut agreement restrict jv joint distribut facilit function jv enabl merck divulg fulli amp product techniqu partner joint distribut fulli benefit commerci advantag partner strong distribut network specif indic joint distribut vaccin sector facilit cooper amp product market plan vaccin made earli stage time engag amp product refer epidemiolog studi orient amp clinic trial activ turn subsequ market final product pharmacovigil observ unexpect effect vaccin involv identif signific health issu enabl advers health risk rectifi absenc joint distribut amp product team reli set data ident product creat form duplic effort burden requir shift amp product batch releas biolog natur vaccin inher risk product batch failur requir constant interfac manufactur distribut team eea countri distribut team releas relev nation control laboratori batch requir appli pharmaceut product batch releas creat daili interdepend team nation distribut prefer account present form vaccin develop vial singl dose multi dose multi chamber syring elimin competit consid creation jv lead elimin competit vaccin market eea reason conclus individu vaccin market view skb current share french hepat market increas creation jv lead elimin competit market true german monoval measl market skb command market competit german monoval rubella market elimin view presenc internation oper vaccin produc skb und wellcom market share remain competit forc market develop posit ii increas intra brand competit jv behr import vaccin distributor germani regard mmr multival merck vaccin wide accept vaccin pmsv absenc jv improv mump strain recit vaccin produc skb updat mump strain enter market competitor berna regist mmr greec und austria mump strain potenti increas penetr eea countri remain effect potenti competit regard futur market observ made skb hepat vaccin regist commerci europ berna product clinic trial germani biocin sclavo product await registr skb varicella vaccin market immunocompromis children pmsv exist vaccin activ amp adapt product healthi children consider conclud skb potenti develop mmrv aricella vaccin market structur creation jv constitut insurmount barrier produc enter futur vaccin market commiss found indic futur vaccin market competit elimin result european jv regard futur paediatr hexaval dtpa polio hib hepat creation jv bring chang market structur merck skb view hepat patent situat recit legal secur posit bring hexaval european market result creation jv jv skb posit conclud basi inform dispos commiss skb possibl develop hexaval pure theoret lpb argument posit vaccin market produc market monoval antigen includ hexaval threaten accept alleg threat base presumpt sale potenti hexaval jv contrari lpb develop view access requir antigen sale mono multival combin hexaval antigen dtpa hib dtpa hib dtp polio remain econom viabl term reason state recit mono limit multival belong market paediatr hexaval vaccin continu sold countri paediatr hexaval gener immun albeit limit number dose brush immun booster protect person commiss basi actual inform possess paediatr hexaval eea countri whilst avail hexaval realiz highli desir object public health health author medic commun countri region accept hexaval gener immun hexaval respond relev epidemiolog recit eea compon hib hepat ii hexaval fit vaccin schedul continu differ larg extent compon polio dtp iii tradit attitud immun antigen neg attitud denmark itali pertussi strong prefer oral polio vaccin countri surmount behr agreement agreement pierr fabr distribut mmr pneumococc vaccin agreement jv agre behr pierr fabr suppli mmr mono bival compon vaccin resal germani franc behr pierr fabr respecit fulfil condit laid commiss regul eec june applic articl treati categori exclus distribut agreement agreement exempt pursuant regul behr agreement relat pneumococc vaccin consid fall foul articl ec treati eea agreement exempt pursuant regul agenc agreement hepat vaccin sole agenc agreement consid fulfil requir laid articl grant individu exempt agreement lead improv distribut jv concentr sale activ maintain numer busi relat larger number dealer deal dealer overcom easili distribut difficulti exist german vaccin sector result linguist legal differ relat medic tradit agreement facilit continu promot sale indispens intens market continu suppli time ration distribut consum allow fair share result benefit german prescrib doctor benefit behr experi establish inform exchang network concentr specif german market produc market parallel import export jv product remain competit elimin multival technolog transfer licenc set agreement regul cooper jv behr develop behr multival multival technolog transfer licenc agreement pure licens agreement ancillari provis relat trademark intellectu properti right undertak parti laid articl commiss regul eec novemb applic articl ec treati categori licens agreement agreement oblig refer articl regul oblig jv licens undertak exploit licens technolog licens territori oblig behr exploit licens technolog germani territori common market reserv jv oblig behr pursu activ polici put behr multival market germani engag advertis specif aim territori establish branch maintain distribut depot behr make sale germani respons unsolicit request oblig behr hepat multival product behr multival jv hepat antigen trademark own jv product registr product own jv fact agreement oblig articl regul appli agreement benefit block exempt sole fact agreement last period longer year allow articl circumst behr benefit provis procur jv antigen behr multival decemb minimum year market possibl behr start due multival technolog licenc develop work multival base antigen jv parti possibl lead seri multival constitut import element technic progress german vaccin market fact agreement guarante minim commerci period year behr multival develop benefit block exempt exclud grant individu exempt case agreement incent behr continu amp work creation multival end year behr agreement benefici consum multival technolog licenc agreement lead sourc multival base jv kei antigen germani come market end agreement behr exploit sever intellectu properti right creat develop multival antigen jv ousid germani agreement lead benefit public health eea countri extens year durat block exempt case individu behr multival indispens possibl behr activ pursu develop coupl year normal end agreement decemb jv skb posit develop compet rang multival competit elimin german market hib manufactur distribut licens agreement agreement enter parti jv behr pierr fabr intervent commiss contribut mainten effect competit german french monoval hib market agreement behr competit german momoval hib market substanti reduc parti jv command control pmsv connaught laboratori merck hib vaccin offer germani amount market grant exclus manufactur licens behr independ vaccin produc distributor enabl behr determin short long term strateg decis relat price quantiti distribut effort devot hib vaccin merck origin permit behr oper independ competitor german hib market agreement contribut improv distribut allow consum fair share result benefit exclus natur licenc indispens behr oper viabl sourc market restor competit situat german monoval hib market agreement fulfil requir laid articl ec treati eea agreement grant individu exempt agreement pierr fabr french monoval hib market equal fulfil requir grant individu exempt reason similar contribut entri competitor french monoval hib market pmsv hib vaccin offer contribut entri vaccin french market paediatr recit durat pursuant articl regul exempt issu limit period view fact jv agreement termin automat end year ii commiss retain abil review actual effect jv competit vaccin market iii account characterist agreement fact natur market involv mean take longer time advantag cooper fulli realiz amp work lead bring vaccin market take excess year commiss conclud exempt decemb meantim commiss follow close evolut vaccin market jv oper context commiss account inform parti undertook provid annual basi recit adopt decis articl provis articl treati articl eea agreement pursuant articl articl declar inapplic set agreement pasteur mérieux sérum vaccin merck amp organ exist activ human vaccin immunoglobulin vivo diagnost sera busi territori defin ec efta jointli control compani pasteur mérieux msd snc jv provis articl treati articl eea agreement pursuant articl articl declar inapplic agenc agreement hepat vaccin multival technolog transfer licenc hib manufactur distribut licenc jv behringwerk ag provis articl treati articl eea agreement pursuant articl articl declar inapplic hib manufactur distribut licenc agreement jv pierr fabr médicament sa exempt appli decemb articl decis address undertak merck amp merck drive whitehous station usa jersei pasteur mérieux sérum vaccin avenu leclerc bp lyon brussel octob commiss karel van miert member commiss oj oj amend version oj oj oj oj oj time commiss assess notifi oper merger regul regul eec juli hear provid articl council regul oj publish version decis inform hereinaft omit pursuant provis articl regul disclosur busi secret commiss commun march council parliament outlin industri polici pharmaceut sector european commun final chapter estim cost million combin includ vaccin combin hepat antigen mening combin mmr varicella combin specif target adult vaccin combin basi adjust diphteria dose pneumococcu flu combin illustr refer merck hepat vaccin vial french doctor tradition prefer vaccin present prefil syring requir dose stabil studi year pneumococc vaccin illustr recit recit german merger law jv assess consid monoval rubella vaccin market de minimi market total turnov dm million product year market case monoval measl market recit recit product facil parti europ relev pmsv transfer jv recit arrang suppli recit mean inform discoveri improv process formula data engin technic shop draw invent shopright trade secret case term agreement gener relat develop germani behr multival product ii jv hib hepat acellular pertussi includ behr multival product sell case behr multival product hepat multival product make made behr multival product germani nothwithstand forego multival includ inform data proprietari parti jv affili licenc pursuant jv affili grant licenc respect matter recit accept health author medic commun multival depend relev epidemiolog histor tradit attitud immun monoval compos mmr vaccin occur eea countri recit recit longer case sweden norwai turnov spain ecu merck total sale spain person dedic vaccin sale skb vaccin turnov trebl vaccin turnov differ due predominantli sale hepat vaccin respect epidemiolog biolog characterist vaccin adapt dosag combin deliveri system knowledg nation distribut prefer present vial singl dose multi dose multi chamber syring import support make epidemiolog studi orient amp clinic activ turn import vaccin market element merck measl vaccin meet current european pharmacopeia standard adopt world health organ criteria heat stabil requir develop world absenc cold chain merck vaccin wide accept europ distribut network dispos cold chain pmsv measl develop programm lead administr protect antigen earlier ag merck retain possibl distribut rubella vaccin germani jv distribut merck pmsv rubella vaccin competit behr pursuant articl eea agreement oj pursuant articl eea agreement oj oblig relat sever intellectu properti right refus grant jv parent suppli jv antigen jv field claus limit behr right develop multival case consid fall scope articl exempt pursuant articl regul